RVPH Stock Overview
A biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
My Notes
Capture your thoughts, links and company narrative
Reviva Pharmaceuticals Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.88 |
| 52 Week High | US$4.83 |
| 52 Week Low | US$0.60 |
| Beta | -0.12 |
| 1 Month Change | -27.97% |
| 3 Month Change | 52.85% |
| 1 Year Change | -54.92% |
| 3 Year Change | -7.39% |
| 5 Year Change | -82.01% |
| Change since IPO | -80.64% |
Recent News & Updates
Recent updates
Reviva Pharmaceuticals: Upcoming Events May Generate Excitement, But Cash Is Low
Dec 11Here's Why Reviva Pharmaceuticals Holdings (NASDAQ:RVPH) Must Use Its Cash Wisely
Aug 24
We're Keeping An Eye On Reviva Pharmaceuticals Holdings' (NASDAQ:RVPH) Cash Burn Rate
Dec 28Reviva Pharmaceuticals drops 9% on $8.5M private placement
Sep 06We're A Little Worried About Reviva Pharmaceuticals Holdings' (NASDAQ:RVPH) Cash Burn Rate
Aug 24Reviva Pharmaceuticals Q2 GAAP loss per share widens
Aug 15Reviva reports positive brilaroxazine results in Aacute Schizophrenia
Apr 26Shareholder Returns
| RVPH | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -4.6% | 0.5% | -2.1% |
| 1Y | -54.9% | 2.3% | 21.3% |
Return vs Industry: RVPH underperformed the US Pharmaceuticals industry which returned 2.3% over the past year.
Return vs Market: RVPH underperformed the US Market which returned 21.3% over the past year.
Price Volatility
| RVPH volatility | |
|---|---|
| RVPH Average Weekly Movement | 23.6% |
| Pharmaceuticals Industry Average Movement | 11.1% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: RVPH's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: RVPH's weekly volatility has increased from 18% to 24% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 15 | Laxminarayan Bhat | www.revivapharma.com |
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company’s lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention–deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer’s disease, and Parkinson’s disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity.
Reviva Pharmaceuticals Holdings, Inc. Fundamentals Summary
| RVPH fundamental statistics | |
|---|---|
| Market cap | US$62.87m |
| Earnings (TTM) | -US$33.01m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.9x
P/E RatioIs RVPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RVPH income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$33.01m |
| Earnings | -US$33.01m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.99 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -0.8% |
How did RVPH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/13 08:17 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Reviva Pharmaceuticals Holdings, Inc. is covered by 8 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Bruce Jackson | Benchmark Company |
| Jason Kolbert | D. Boral Capital LLC. |